{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.40","value":"1.3"},{"groupId":"OG001","spread":"27.04","value":"-4.4"},{"groupId":"OG002","spread":"30.82","value":"2.0"}]}],"title":"Cycle 3, Day 1 (n=129, 115, 125)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.36","value":"-4.9"},{"groupId":"OG001","spread":"27.47","value":"-6.1"},{"groupId":"OG002","spread":"29.24","value":"-0.4"}]}],"title":"Cycle 5, Day 1 (n=114, 98, 107)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.58","value":"-3.3"},{"groupId":"OG001","spread":"31.86","value":"-8.6"},{"groupId":"OG002","spread":"28.61","value":"-4.7"}]}],"title":"Cycle 7, Day 1 (n=89, 79, 84)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.55","value":"-4.2"},{"groupId":"OG001","spread":"28.16","value":"-8.1"},{"groupId":"OG002","spread":"28.55","value":"-1.0"}]}],"title":"Cycle 9, Day 1 (n=87, 66, 67)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.67","value":"-11.6"},{"groupId":"OG001","spread":"29.54","value":"-7.9"},{"groupId":"OG002","spread":"31.72","value":"2.8"}]}],"title":"Cycle 11, Day 1 (n=71, 61, 65)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.00","value":"-10.2"},{"groupId":"OG001","spread":"32.87","value":"-8.5"},{"groupId":"OG002","spread":"35.16","value":"1.0"}]}],"title":"Cycle 13, Day 1 (n=67, 52, 61)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"167"}],"units":"Participants"}],"description":"The European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact).\n\nThe EORTC QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received bortezomib (Velcade) 1.3 mg/m\\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG000","title":"Bortezomib and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG001","title":"Bortezomib, Thalidomide, and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"OG002","title":"Bortezomib, Melphalan and Prednisone"}],"paramType":"MEAN","populationDescription":"Intent-to-treat population with available data at each time point (indicated by \"n\").","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1 of Cycles 3, 5, 7, 9, 11 and 13","title":"Change From Baseline in EORTC QLQ-C30 - Global Health Status","type":"SECONDARY","unitOfMeasure":"units on a scale"}